4,5,6,7-四氢苯并[B]噻吩二甲酸 | 40133-07-1

• 物质功能分类: 医药中间体 - 杂环化合物 - 噻吩类化合物
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 噻吩类
• 中文名称: 4,5,6,7-四氢苯并[B]噻吩二甲酸
• 中文别名: 4,5,6,7-四氢苯并[b]噻吩-2-羧酸
• 英文名称: 4,5,6,7-tetrahydrobenzo[b]thiophene-2-carboxylic acid
• 英文别名: 4,5,6,7-tetrahydro-1-benzothiophene-2-carboxylic acid
• CAS: 40133-07-1
• 化学式: C₉H₁₀O₂S
• mdl: MFCD00464469
• 分子量: 182.243
• InChiKey: ROLXOQXKNDKXTA-UHFFFAOYSA-N

物化性质

• 熔点：
  196℃
• 沸点：
  368.1±42.0 °C(Predicted)
• 密度：
  1.317±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.7
• 重原子数：
  12
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.444
• 拓扑面积：
  65.5
• 氢给体数：
  1
• 氢受体数：
  3

安全信息

• 危险等级：
  IRRITANT
• 海关编码：
  2934999090
• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H315,H319,H335

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
4,5,6,7-Tetrahydro-benzo[b]thiophene-2-carboxylic acid
Product Name:
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.
H315: Causes skin irritation
H319: Causes serious eye irritation
H335: May cause respiratory irritation
P261: Avoid breathing dust/fume/gas/mist/vapours/spray
Wear protective gloves/protective clothing/eye protection/face protection
P280:
P305+P351+P338: IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses if present
and easy to do – continue rinsing
P304+P340: IF INHALED: Remove victim to fresh air and keep at rest in a position comfortable for breathing
P405: Store locked up

---

Section 3. Composition/information on ingredients.
4,5,6,7-Tetrahydro-benzo[b]thiophene-2-carboxylic acid
Ingredient name:
CAS number: 40133-07-1

---

Section 4. First aid measures
Immediately wash skin with copious amounts of water for at least 15 minutes while removing
Skin contact:
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.
Ingestion:

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Storage: Store in closed vessels, refrigerated.

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Not specified
Appearance:
Boiling point: No data
Melting point: No data
Flash point: No data
Density: No data
Molecular formula: C9H10O2S
Molecular weight: 182.2

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, sulfur oxides.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  4,5,6,7-四氢苯并[B]噻吩二甲酸 在 草酰氯 、 N,N-二异丙基乙胺 、 N,N-二甲基甲酰胺 作用下， 以 2-甲基四氢呋喃 、 二氯甲烷 为溶剂， 反应 1.33h， 生成 N-(2-methyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)-4,5,6,7-tetrahydrobenzo[b]thiophene-2-carboxamide
  参考文献：
  名称：

  有力和选择性的布鲁顿酪氨酸激酶抑制剂：GDC-0834的发现

  摘要：

  SAR研究专注于改善先前报道的有效和选择性Btk抑制剂CGI-1746（1）的药代动力学（PK）特性，从而产生了临床候选药物GDC-0834（2），该药物保留了CGI-1746的效力和选择性，但在临床前动物模型中改善了PK。基于结构的设计工作推动了这项工作，因为在溶剂暴露区域以及“ H3结合口袋”处都对1的修饰进行了研究。但是，体外代谢评价为2揭示了一种非CYP介导的代谢过程，在人类中比临床前物种（小鼠，大鼠，狗，猕猴）更普遍，从而导致在预测人类药代动力学方面存在高度不确定性。由于其有希望的效价，选择性和临床前功效，因此在健康志愿者中进行了单剂量IND并接受了2项单剂量I期试验，以快速评估人的药代动力学。在人类中，发现2在将四氢苯并噻吩部分连接至中央苯胺环的环外酰胺键上非常不稳定，从而导致母体药物暴露不足。该信息为备份计划和改进抑制剂的发现提供了信息。

  DOI：

  10.1016/j.bmcl.2015.01.032
• 作为产物：
  描述：

  1-(4,5,6,7-tetrahydro-benzo[b]thiophen-2-yl)-ethanone 在 1,4-二氧六环 、 alkaline aqueous potassium hypobromite solution 作用下， 生成 4,5,6,7-四氢苯并[B]噻吩二甲酸
  参考文献：
  名称：

  Cagniant; Cagniant, Bulletin de la Societe Chimique de France, 1953, p. 62,68, 713, 717

  摘要：

  DOI：

文献信息

• COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM
  申请人：Whitten Jeffrey P.

  公开号：US20110263612A1

  公开（公告）日：2011-10-27

  Described herein are compounds and pharmaceutical compositions containing such compounds, which modulate the activity of store-operated calcium (SOC) channels. Also described herein are methods of using such SOC channel modulators, alone and in combination with other compounds, for treating diseases or conditions that would benefit from inhibition of SOC channel activity.

  本文描述了含有这些化合物的化合物和药物组合物，这些化合物调节储存操作钙（SOC）通道的活性。本文还描述了使用这种SOC通道调节剂的方法，单独或与其他化合物结合，用于治疗需要抑制SOC通道活性的疾病或症状。
• [1,2,4]Triazolo[1,5-<i>a</i>]pyrimidine Phosphodiesterase 2A Inhibitors: Structure and Free-Energy Perturbation-Guided Exploration
  作者：Gary Tresadern、Ingrid Velter、Andrés A. Trabanco、Frans Van den Keybus、Gregor J. Macdonald、Marijke V. F. Somers、Greet Vanhoof、Philip M. Leonard、Marieke B. A. C. Lamers、Yves E. M. Van Roosbroeck、Peter J. J. A. Buijnsters

  DOI：10.1021/acs.jmedchem.0c01272

  日期：2020.11.12

  We describe the hit-to-lead exploration of a [1,2,4]triazolo[1,5-a]pyrimidine phosphodiesterase 2A (PDE2A) inhibitor arising from high-throughput screening. X-ray crystallography enabled structure-guided design, leading to the identification of preferred substructural components. Further rounds of optimization used relative binding free-energy calculations to prioritize different substituents from

  我们描述了一种由高通量筛选引起的[1,2,4]三唑并[1,5- a ]嘧啶磷酸二酯酶2A（PDE2A）抑制剂的直接研究。X射线晶体学使结构导向设计成为可能，从而确定了首选的子结构组件。进一步的优化使用相对结合自由能计算来确定来自较大可及化学空间的不同取代基的优先级。对265种假定的PDE2A抑制剂进行了自由能扰动（FEP）计算，并合成了100种化合物，它们代表了较大的预期应用范围，可提供具有2340至0.89 nM的IC 50值的出乎意料的活性分子。铅化合物46由FEP计算得出的结果显示，PDE2A抑制IC 50为1.3±0.39 nM，相对于其他PDE酶具有约100倍的选择性，干净的细胞色素P450分布，体内靶标占有率，并有望进一步优化铅。
• [EN] COMPOUNDS FOR TREATING VIRAL INFECTIONS<br/>[FR] COMPOSÉS POUR TRAITER DES INFECTIONS VIRALES
  申请人：PASTEUR INSTITUT KOREA

  公开号：WO2015158908A1

  公开（公告）日：2015-10-22

  The present invention relates to small molecule compounds and their use in the treatment of diseases, in particular viral diseases, in particular hepatitis C virus (HCV).

  本发明涉及小分子化合物及其在治疗疾病中的应用，特别是病毒性疾病，尤其是丙型肝炎病毒（HCV）。
• CERTAIN SUBSTITUTED AMIDES, METHOD OF MAKING, AND METHOD OF USE THEREOF
  申请人：BLOMGREN Peter A.

  公开号：US20090082330A1

  公开（公告）日：2009-03-26

  Compounds of Formula I that inhibit Btk are described herein. Pharmaceutical compositions comprising at least one compound of Formula I, together with at least one pharmaceutically acceptable vehicle chosen from carriers, adjuvants, and excipients, are described. Methods of treating patients suffering from certain diseases responsive to inhibition of Btk activity and/or B-cell activity are described. Methods for determining the presence of Btk in a sample are described.

  公式I的化合物能够抑制Btk，本文中对此进行了描述。描述了包含至少一个公式I化合物的药物组合物，以及至少一个从载体、佐剂和辅料中选择的药用辅料。描述了治疗患有对Btk活性抑制和/或B细胞活性有反应的某些疾病患者的方法。还描述了用于确定样本中存在Btk的方法。
• ALKYLATED PIPERAZINE COMPOUNDS
  申请人：Genentech, Inc.

  公开号：US20130116245A1

  公开（公告）日：2013-05-09

  Alkylated piperazine compounds of Formula I are provided, including stereoisomers, tautomers, and pharmaceutically acceptable salts thereof, useful for inhibiting Btk kinase, and for treating immune disorders such as inflammation mediated by Btk kinase. Methods of using compounds of Formula I for in vitro, in situ, and in vivo diagnosis, and treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed.

  提供了公式I的烷基化哌嗪化合物，包括其立体异构体、互变异构体和药学上可接受的盐，用于抑制Btk激酶，并用于治疗由Btk激酶介导的炎症等免疫紊乱。公开了使用公式I化合物进行哺乳动物细胞中的体外、体内和体内诊断以及治疗这类疾病或相关病理条件的方法。